Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Upfront Fee Material Information?

<< Previous

Bullboard Posts

Next >>

Comment by biorunon Jul 07, 2022 10:11am

146 Views

Post# 34808106

RE:RE:RE:RE:RE:Upfront Fee Material Information?

yes, they are required to report all money coming into the coffers as you indicate, but abbvie also has to report a 10k in august where they "may" also be required to disclose certain details. we will see what that brings.

if that does surface and it is in fact more than lcfsa insists, then expect an immediate revaluation within the hour. right now we are trading with near full doubt the economic impact of the deal with abbvie is negligible, thanks to the bashers here.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China